Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Alkermes ( ($ALKS) ) has provided an update. On August 12, 2026, Alkermes plc amended a credit agreement originally signed on February 12, 2026 wit...

Alkermes Amends Credit Agreement to Lower Borrowing Costs

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alkermes (ALKS), BioMarin Pharmaceutical (BMRN) and ...

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), BioMarin Pharmaceutical (BMRN) and Cresco Labs (OtherCRLBF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CSL (CMXHF) and Alkermes (ALKS). CSL (CMXHF) In a ...

Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Alkermes (ALKS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Incyte (INCY) with bullish senti...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS) and Universal Health (UHS). Alkermes (ALKS) Needh...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Universal Health (UHS)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Alkermes, with a price target of $65.00. According to TipR...

Piper Sandler Reaffirms Their Buy Rating on Alkermes (ALKS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Celldex (CLDX) with bullish sent...

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Harmony Biosciences Holdings (HRMY) and Alkermes (...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALKS	$49.06	-0.79%	1.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALKS	$49.06	-0.8%	1.27M
3
4
5
6

ALKS

Get Alkermes plc Data in Excel

Get Alkermes plc Data in Excel